Novavax, Inc. (NASDAQ:NVAX) Director Sells $105,675.00 in Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 7,500 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $14.09, for a total value of $105,675.00. Following the sale, the director now owns 61,760 shares in the company, valued at approximately $870,198.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Novavax Trading Down 6.4 %

Shares of NASDAQ:NVAX opened at $13.11 on Thursday. The company has a 50 day moving average of $11.63 and a 200-day moving average of $7.11. Novavax, Inc. has a one year low of $3.53 and a one year high of $23.86.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.01). The business had revenue of $93.90 million for the quarter, compared to analysts’ expectations of $71.32 million. The business’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($3.41) earnings per share. Research analysts forecast that Novavax, Inc. will post 0.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NVAX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised shares of Novavax from an “underweight” rating to a “neutral” rating in a report on Friday, May 10th. Bank of America increased their price target on shares of Novavax from $12.00 to $18.00 and gave the company a “neutral” rating in a research note on Friday, June 14th. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Novavax in a report on Monday, May 13th. B. Riley upped their price objective on Novavax from $11.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, May 23rd. Finally, TD Cowen lifted their target price on Novavax from $5.00 to $10.00 and gave the company a “hold” rating in a research note on Monday, May 13th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Novavax currently has a consensus rating of “Hold” and an average target price of $19.00.

Institutional Investors Weigh In On Novavax

A number of institutional investors have recently made changes to their positions in the stock. Edgestream Partners L.P. lifted its stake in Novavax by 23.7% in the first quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 2,447 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Novavax by 31.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 11,298 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 2,711 shares during the period. Swedbank AB bought a new position in Novavax during the 1st quarter worth approximately $26,000. Tower Research Capital LLC TRC grew its holdings in Novavax by 102.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,944 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 7,072 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Novavax by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 56,065 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 8,128 shares in the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.